I. Adjaho

Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Cote dIvoire

M. Diomande, F. Luquero, B. Nikolay, 2022, medRxiv.

Breakthrough treatments for Ebola virus disease, but no access-what went wrong, and how can we do better?

P. Olliaro, Y. Boum, E. Torreele, 2023, Lancet. Infectious Diseases (Print).

On the importance and challenges of global access to proven life-saving treatments for Ebolavirus - Authors' reply.

P. Olliaro, Y. Boum, E. Torreele, 2023, The Lancet. Infectious diseases.

Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Côte d’Ivoire

F. Luquero, B. Nikolay, K. Porten, 2023, PLOS global public health.